Big Data - Epidemiology of Critical Illness and Sepsis
大数据——危重疾病和败血症的流行病学
基本信息
- 批准号:10923699
- 负责人:
- 金额:--
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:
- 资助国家:美国
- 起止时间:至
- 项目状态:未结题
- 来源:
- 关键词:Academic Medical CentersAcuteAdmission activityAdrenal Cortex HormonesAlberta provinceAlgorithmsAntibioticsAntimicrobial ResistanceBacterial InfectionsBig DataBiological MarkersBody mass indexCOVID-19COVID-19 mortalityCOVID-19 pandemicCOVID-19 patientCOVID-19 riskCanadaCandidiasisCardiacCaringCharacteristicsClindamycinClinicalClinical DataClinical TrialsCodeCollaborationsCommunicable DiseasesCommunitiesCritical CareCritical IllnessDataData SetDevelopmentDiseaseDoseElectronic Health RecordEpidemiologyExotoxinsFDA Emergency Use AuthorizationFrequenciesFunctional disorderGenerationsHealthcareHematologic NeoplasmsHospital MortalityHospitalizationHospitalsHydroxychloroquineImmuneIncidenceInfectionInflammationIntravenous ImmunoglobulinsIntubationInvestigationLiteratureLower Respiratory Tract InfectionMachine LearningMediatingMedicineMeta-AnalysisMethodsModelingMorbidity - disease rateMortality DeclineNecrotizing fasciitisObesityObservational StudyOncologyOntarioOrganOutcomeOutcome StudyPatient AdmissionPatient CarePatient-Focused OutcomesPatientsPatternPerformancePharmaceutical PreparationsPopulationPrevalenceProviderPublishingQuality of CareRandomized, Controlled TrialsResearchResearch PersonnelResourcesRiskRisk AdjustmentRisk FactorsSARS-CoV-2 B.1.1.529SARS-CoV-2 infectionSepsisSeptic ShockSeveritiesSeverity of illnessShockStreptococcal InfectionsStreptococcus Group BStreptococcus pyogenesSurveysT cell therapyT-LymphocyteTestingTherapeuticTimeToxic effectTriageUS StateUndifferentiatedUnited StatesVaccinationVaccineeValidationVariantVasoconstrictor AgentsVentilatorbeta-Lactamsbooster vaccineburden of illnessclinical epidemiologycohortcommunity transmissioncostcytokinecytokine release syndromedrug repurposingepidemiologic dataimprovedimproved outcomeindexinginfection rateinterestlung injurymedical schoolsmortalitymortality riskopioid useopioid userpandemic diseasepre-pandemicprocalcitoninrandomized trialrepositoryrespiratorysmoke inhalationsystematic reviewtrenduptakevariants of concernventilation
项目摘要
Critical illness and sepsis (including critical disease from COVID-19) are associated with significant morbidity and mortality, especially in conditions where existing therapeutic strategies remain suboptimal. Our primary aim is to leverage large repositories of granular clinical data to better understand the clinical epidemiology of critical illness, sepsis and serious infections, including defining illness burden, risk factors and clinical impact.
The pathophysiology of organ dysfunction in streptococcal infection is attributed to inflammation mediated by exotoxin-mediated cytokine cascade. Clindamycin neutralizes exotoxin released by Group A Streptococcus. In a large propensity-matched cohort of patients we found that clindamycin added as an adjunct to beta lactam therapy was associated with improved survival in Group A streptococcal infection but also identified a trend toward harm when used in non-Group A, Group B streptococcal infections. These findings warrant confirmation in randomized trials.
Antibiotic overuse remains a significant problem in the critically ill and is associated with toxicity and development of antimicrobial resistance. Among critically ill patients with suspected or confirmed sepsis in a larger cohort of US hospitals, we found that use of procalcitonin significantly reduced duration of antibiotic use without worsening outcomes. We confirmed these findings in a meta-analysis of randomized controlled trials. We also described real world use patterns of this biomarker using large an enhanced administrative dataset and studied its performance characteristics in patients with suspected bloodstream infection.
Most estimates of sepsis incidence and mortality in existing literature are estimated using claims data. Unfortunately claims based data are subject to a variety of biases. We estimate 10-year trends in the incidence and outcome of septic shock using clinical indicators in a cohort of academic medical centers in the United States and compared it to estimates obtained using claims based data. We found that the prevalence of septic shock was rising and mortality declining over time, albeit, both less vigorously than suggested by claims based methods. In addition, we identified obesity as being associated with better outcomes in more than 50,000 patients with clinical indicators of sepsis at US hospitals. In collaboration with investigators at Harvard Medical School, we were able to study the differences in characteristics and outcomes of sepsis that originates in the community versus the hospital as well as studied variation in identifying sepsis and organ dysfunction using claims versus electronic health records. Along with the same group, we were able to assess how a severity score performs to identify patients with undifferentiated sepsis.
In collaboration with investigators at Harvard Department of Population Medicine, we found that models incorporating electronic health record data accurately predict hospital mortality for patients who meet an operational definition of sepsis based on clinical indicators and outperforms models using administrative data alone. This operational definition may enable more meaningful comparisons of hospital sepsis outcomes and provide an important window into quality of care. We also found that incorporating clinical data into risk adjustment substantially changes rankings of hospitals' sepsis mortality rates compared with using administrative data alone. Comprehensive risk adjustment using both administrative and clinical data is necessary before comparing hospitals by sepsis mortality rates. Our study on short stays for sepsis underscore the incomplete uptake of Sepsis-3 definitions, the breadth of illness severities encompassed by both traditional and new sepsis definitions, and the possibility that some patients with sepsis recover very rapidly. Our study on association between opioid use and sepsis highlight the disproportionately high mortality burden associated with younger opioid users developing sepsis. With this group, we also identified potential biases in time-to-antibiotic studies in sepsis.
As part of the ICU-CAR initiative, a research group of critical care and oncology providers, we participated in a study that surveyed clinicians from multiple ICUs in the US caring for patients with hematologic malignancies receiving T-cell directed therapy to understand prevailing practices around the management of cytokine release syndrome T Cell toxicities. Immune suppressed patients often develop invasive candidiasis. We used this entity as a proof of concept to show how machine learning can capture risk factors for infectious diseases of interest.
In collaboration with the CDC, we found that hospital surges are detrimental to survival for patients admitted with COVID-19. With the CDC group, we also found that risk of hospital-onset COVID-19 increases in the setting of high community transmission. In collaboration with a Canadian research group, we found that surges were particularly detrimental for non-COVID patients with conditions that tend to require the same healthcare resources as patients with COVID-19. With investigator from the same group, we found that vaccine booster doses were associated with improved outcomes in vaccinated patients with COVID-19 who were admitted to the ICU. We also found that the risk of COVID-19 reinfection remained low up to 9 months since index infection but our findings do not include the period where variants of concern were prevalent in the U.S. We found that hydroxychloroquine use fell sharply even before the emergency use authorization for this drug was revoked. We also found that corticosteroids were being used frequently in ventilated COVID-19 patients well before its benefit was publicly known from clinical trials. We found that inter hospital transport of patients with lower respiratory tract infections during the pandemic was just as safe as compared to during pre-pandemic times. We also found that the SOFA score, an acute severity score was a poor predictor of mortality in intubated patients with COVID-19, and yet most US States use it in their Crisis Standards of Care ventilator triage algorithms were heavily weighted by the SOFA score. We completed an investigation to test whether the modified 4 C score, a COVID-19 specific severity score performs adequately in a surge setting and over time, to test its candidacy for triage algorithms.
危重疾病和败血症(包括COVID-19引起的危重疾病)与显著的发病率和死亡率相关,特别是在现有治疗策略仍不理想的情况下。我们的主要目标是利用大量的临床数据来更好地了解危重疾病、败血症和严重感染的临床流行病学,包括定义疾病负担、风险因素和临床影响。
项目成果
期刊论文数量(33)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Outcomes Among Patients Hospitalized With Non-COVID-19 Conditions Before and During the COVID-19 Pandemic in Alberta and Ontario, Canada.
在艾伯塔省和加拿大安大略省的COVID-19大流行之前和期间,患有非旋转19号病情的患者的结局。
- DOI:10.1001/jamanetworkopen.2023.23035
- 发表时间:2023-07-03
- 期刊:
- 影响因子:13.8
- 作者:McAlister, Finlay A.;Chu, Anna;Qiu, Feng;Dong, Yuan;van Diepen, Sean;Youngson, Erik;Yu, Amy Y. X.;de Mestral, Charles;Ross, Heather J.;Austin, Peter C.;Lee, Douglas S.;Kadri, Sameer S.;Wijeysundera, Harindra C.
- 通讯作者:Wijeysundera, Harindra C.
Risk Adjustment for Sepsis Mortality to Facilitate Hospital Comparisons Using Centers for Disease Control and Prevention's Adult Sepsis Event Criteria and Routine Electronic Clinical Data.
使用疾病控制和预防中心的成人脓毒症事件标准和常规电子临床数据对脓毒症死亡率进行风险调整,以促进医院比较。
- DOI:10.1097/cce.0000000000000049
- 发表时间:2019
- 期刊:
- 影响因子:0
- 作者:Rhee,Chanu;Wang,Rui;Song,Yue;Zhang,Zilu;Kadri,SameerS;Septimus,EdwardJ;Fram,David;Jin,Robert;Poland,RussellE;Hickok,Jason;Sands,Kenneth;Klompas,Michael
- 通讯作者:Klompas,Michael
Impact of Risk Adjustment Using Clinical vs Administrative Data on Hospital Sepsis Mortality Comparisons.
使用临床与管理数据进行风险调整对医院脓毒症死亡率比较的影响。
- DOI:10.1093/ofid/ofaa213
- 发表时间:2020
- 期刊:
- 影响因子:4.2
- 作者:Rhee,Chanu;Li,Zhonghe;Wang,Rui;Song,Yue;Kadri,SameerS;Septimus,EdwardJ;Chen,Huai-Chun;Fram,David;Jin,Robert;Poland,Russell;Sands,Kenneth;Klompas,Michael
- 通讯作者:Klompas,Michael
Prevalence and Clinical Characteristics of Patients With Sepsis Discharge Diagnosis Codes and Short Lengths of Stay in U.S. Hospitals.
- DOI:10.1097/cce.0000000000000373
- 发表时间:2021-03
- 期刊:
- 影响因子:0
- 作者:Kuye I;Anand V;Klompas M;Chan C;Kadri SS;Rhee C
- 通讯作者:Rhee C
Real-World Inpatient Use of Medications Repurposed for Coronavirus Disease 2019 in United States Hospitals, March-May 2020.
- DOI:10.1093/ofid/ofaa616
- 发表时间:2021-03
- 期刊:
- 影响因子:4.2
- 作者:Kadri SS;Demirkale CY;Sun J;Busch LM;Strich JR;Rosenthal N;Warner S
- 通讯作者:Warner S
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Sameer Kadri其他文献
Sameer Kadri的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Sameer Kadri', 18)}}的其他基金
Big Data - Epidemiology of Critical Illness and Sepsis
大数据——危重疾病和败血症的流行病学
- 批准号:
10473358 - 财政年份:
- 资助金额:
-- - 项目类别:
Big Data - Epidemiology of Critical Illness and Sepsis
大数据——危重疾病和败血症的流行病学
- 批准号:
10250941 - 财政年份:
- 资助金额:
-- - 项目类别:
相似海外基金
Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
- 批准号:
MR/Y009568/1 - 财政年份:2024
- 资助金额:
-- - 项目类别:
Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
- 批准号:
10090332 - 财政年份:2024
- 资助金额:
-- - 项目类别:
Collaborative R&D
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
- 批准号:
MR/X02329X/1 - 财政年份:2024
- 资助金额:
-- - 项目类别:
Fellowship
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
- 批准号:
MR/X021882/1 - 财政年份:2024
- 资助金额:
-- - 项目类别:
Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
- 批准号:
2312694 - 财政年份:2024
- 资助金额:
-- - 项目类别:
Standard Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
- 批准号:
EP/Y003527/1 - 财政年份:2024
- 资助金额:
-- - 项目类别:
Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
- 批准号:
EP/Y030338/1 - 财政年份:2024
- 资助金额:
-- - 项目类别:
Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
- 批准号:
MR/X029557/1 - 财政年份:2024
- 资助金额:
-- - 项目类别:
Research Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
- 批准号:
24K19395 - 财政年份:2024
- 资助金额:
-- - 项目类别:
Grant-in-Aid for Early-Career Scientists